SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001558370-18-001866
Filing Date
2018-03-12
Accepted
2018-03-12 08:18:20
Documents
85
Period of Report
2017-12-31

Document Format Files

Seq Description Document Type Size
1 10-K acrs-20171231x10k.htm 10-K 3529804
2 EX-21.1 acrs-20171231ex211e8825c.htm EX-21.1 7181
3 EX-23.1 acrs-20171231ex2314a3db9.htm EX-23.1 4026
4 EX-31.1 acrs-20171231ex3118e0cd2.htm EX-31.1 10651
5 EX-31.2 acrs-20171231ex312d050a6.htm EX-31.2 9944
6 EX-32.1 acrs-20171231ex321ab80e7.htm EX-32.1 12470
7 GRAPHIC acrs20171231x10k001.jpg GRAPHIC 39536
8 GRAPHIC acrs20171231x10k002.jpg GRAPHIC 20313
  Complete submission text file 0001558370-18-001866.txt   11933354

Data Files

Seq Description Document Type Size
9 EX-101.INS acrs-20171231.xml EX-101.INS 2729807
10 EX-101.SCH acrs-20171231.xsd EX-101.SCH 58275
11 EX-101.CAL acrs-20171231_cal.xml EX-101.CAL 79754
12 EX-101.DEF acrs-20171231_def.xml EX-101.DEF 233310
13 EX-101.LAB acrs-20171231_lab.xml EX-101.LAB 644182
14 EX-101.PRE acrs-20171231_pre.xml EX-101.PRE 449806
Mailing Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355
Business Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355 484-321-5554
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-37581 | Film No.: 18682123
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences